Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage biopharma focused on diseases of the central nervous system, rose more than 26% as of 11:35 a.m. EDT Wednesday. The big jump came in response to the company sharing some upbeat regulatory news related to its lead compound lumateperone.
Management let investors know that the FDA has completed its review of the additional data that was submitted related to its nonclinical animal toxicology studies. The agency had previously raised concerns about lumateperone's safety since elevated levels of drug-related metabolites that were found in certain species of animal. In response, they asked Intra-Cellular to provide additional data to help show that the drug was safe for use in humans.
Investors learned on Wednesday that Intra-Cellular presented "adequate data to support its position that the metabolic pathway in the animal species is distinctive from humans, which indicates that the toxicity observed in the animal species is not relevant to humans."
In response to this good news, management said it remains on plan to submit the drug for approval as a hopeful treatment of schizophrenia by mid-2018.
Given the update, it is easy to understand why traders are cheering.
There's no doubt that investors were relieved to hear this news. After all, lumateperone is the company's lead product candidate, so if it was going to be pulled over potential safety issues then it would have blown a hole in the bull case for owning the company's stock.
Does this mean it will be smooth sailing for investors from here? That's always a possibility, that caution is warranted. Schizophrenia is a crowded disease state that companies like Bristol-Myers Squibb, AstraZeneca, and Johnson & Johnson have targeted with success for years. Since lumateperone's phase 3 data showed that it failed to outperform a placebo, I have a hard time believing the drug will be able to win over providers and insurers even if it does manage to gain FDA approval. For that reason, I think the smart move is to look elsewhere for investment opportunities.
10 stocks we like better than Intra-Cellular TherapiesWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Intra-Cellular Therapies wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017